Spero Therapeutics Inc (SPRO) Forecasted to Post FY2018 Earnings of ($3.69) Per Share

Spero Therapeutics Inc (NASDAQ:SPRO) – Research analysts at Cantor Fitzgerald issued their FY2018 earnings per share (EPS) estimates for Spero Therapeutics in a research note issued on Monday. Cantor Fitzgerald analyst L. Chen expects that the company will post earnings of ($3.69) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $27.00 price objective on the stock.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Thursday, December 14th. The company reported ($36.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.43) by ($33.59). The business had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $0.20 million.

Other research analysts also recently issued research reports about the company. Oppenheimer set a $30.00 price objective on Spero Therapeutics and gave the stock a “buy” rating in a report on Thursday, January 11th. ValuEngine raised Spero Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research downgraded Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Bank of America assumed coverage on Spero Therapeutics in a report on Monday, November 27th. They set a “neutral” rating on the stock. Finally, Stifel Nicolaus began coverage on Spero Therapeutics in a report on Monday, November 27th. They set a “buy” rating and a $26.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Spero Therapeutics presently has an average rating of “Hold” and an average price target of $24.25.

Spero Therapeutics (NASDAQ:SPRO) traded down $0.36 during trading hours on Wednesday, reaching $11.20. The company’s stock had a trading volume of 15,600 shares, compared to its average volume of 24,580. Spero Therapeutics has a 12-month low of $9.84 and a 12-month high of $15.40.

Institutional investors have recently modified their holdings of the business. Dean Capital Investments Management LLC bought a new stake in shares of Spero Therapeutics in the 4th quarter valued at $118,000. California Public Employees Retirement System bought a new stake in shares of Spero Therapeutics in the 4th quarter valued at $294,000. BlackRock Inc. bought a new stake in shares of Spero Therapeutics in the 4th quarter valued at $2,830,000. AWM Investment Company Inc. bought a new stake in shares of Spero Therapeutics in the 4th quarter valued at $4,112,000. Finally, Artal Group S.A. bought a new stake in shares of Spero Therapeutics in the 4th quarter valued at $4,113,000. Institutional investors own 9.85% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Spero Therapeutics Inc (SPRO) Forecasted to Post FY2018 Earnings of ($3.69) Per Share” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/14/spero-therapeutics-inc-spro-forecasted-to-post-fy2018-earnings-of-3-69-per-share.html.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply